Cancer is the second leading cause of death in the United States. Furthermore, it contributes to a significant number of emergency department (ED) visits, and patients with cancer are much more likely to bounce back to the ED than the general population. Cancer patients are often immunosuppressed and commonly have altered physiology that predisposes them to a variety of complex pathophysiologic conditions. In a renaissance era of novel cancer therapies (including checkpoint inhibitors and chimeric antigen receptor–modified T-cell [CAR-T] therapy), it is imperative that emergency physicians (EPs) are educated on the common complications from cancer and cancer therapies.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Emergency Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect